Abbott, Nestle, Meiji Holdings CO., LTD and B. Braun Melsungen AG are Dominating the Market for Global Enteral Feeding Formula Market in 2019


Abbott founded in 1888, headquarters in Illinois, U.S., and focuses on manufactures products for diagnostics, medical devices, nutrition and branded generic pharmaceuticals.  Company is engaged in providing products in segments such as established pharmaceuticals, nutritionals, diagnostics, cardiovascular and neuromodulation and others.

Access Full Report:

The company has its presence in Americas, Asia Pacific, Europe, Middle East and South Africa.

  • In August 2017, Abbott announced the partnership with the Changi General Hospital (CGH)  which is supported by the Singapore Economic Development Board, to set up a Nutritional Health for the Elderly Reference Centre (NHERC) in Singapore. This partnership will help the company to drive and transform the healthcare professional in Singapore.


Nestle, founded in 1866 and based in Vevey, Switzerland. The company focuses on developing products in food and beverages. The company is engaged in providing products in different segments such as zone AMS, zone EMENA, zone AOA, nestle nutrition, nestle waters and other businesses.

The company has its presence in Netherland, United states, China, Germany, Japan, France, India and Others.

  • In December 2017, Nestlé announced to acquire privately-held Atrium Innovations to develop the new nutritional products. The product range of the Atrium Innovations will enhance the portfolio of the company by enabling consumers to address their health and wellness goals.

Meiji Holdings CO., LTD:

Meiji Holdings CO., LTD. founded in 2009 and based in Tokyo, Japan. The company is engaged in providing essential products such dairy products, confectioneries, nutritionals and pharmaceuticals. Company provides products in different segments such as food segment and pharmaceutical segment. The company has its presence in Asia-Pacific, Americas, Europe, Middle East Africa..

  • In March 2018, Meiji Holdings Co., Ltd., announced an agreement with Arysta LifeScience Corporation through which the company will be signing a license agreement for a new insecticide. With this agreement Meiji will receive an upfront payment as well as developmental milestone.